Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02041091 · ClinicalTrials.gov registry record · Phase 3
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 226
- Enrollment target
NCT02041091 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 226 participants.
The verdict
NCT02041091, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 226 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the amount of tabalumab in the blood after it is given by two different injection methods - A traditional syringe or a spring loaded syringe for 12 weeks. Participants may continue to receive study drug for up to 52 weeks.
Interventions
- DRUG Tabalumab Auto-Injector
- DRUG Tabalumab Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02041091
The ClinicalTrials.gov registry entry for NCT02041091 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tabalumab Auto-Injector is the first listed.
NCT02041091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02041091 about?
NCT02041091 is a clinical study titled "A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus". The purpose of this study is to evaluate the amount of tabalumab in the blood after it is given by two different injection methods - A traditional syringe or a spring loaded syringe for 12 weeks. Participants may continue to receive study drug for up to 52 weeks.
What is the current status of trial NCT02041091?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 226 participants. The study started on 2014-01. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02041091?
The interventions under investigation include: Tabalumab Auto-Injector (DRUG), Tabalumab Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT02041091?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.